304 related articles for article (PubMed ID: 18508564)
1. Novel aspects of the renin-angiotensin-aldosterone-system.
Wolf G
Front Biosci; 2008 May; 13():4993-5005. PubMed ID: 18508564
[TBL] [Abstract][Full Text] [Related]
2. [The renin-angiotensin-aldosterone system -- more complex as previously thought].
Wolf G
Med Klin (Munich); 2005 Aug; 100(8):471-7. PubMed ID: 16096728
[TBL] [Abstract][Full Text] [Related]
3. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
Remuzzi G; Perico N; Macia M; Ruggenenti P
Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system and progression of renal disease.
Rüster C; Wolf G
J Am Soc Nephrol; 2006 Nov; 17(11):2985-91. PubMed ID: 17035613
[TBL] [Abstract][Full Text] [Related]
5. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
6. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway.
Wolf G
Kidney Int; 2006 Dec; 70(11):1914-9. PubMed ID: 16985515
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
Wolf G; Ritz E
Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
[TBL] [Abstract][Full Text] [Related]
8. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
9. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
10. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
11. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Li XC; Zhang J; Zhuo JL
Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
[TBL] [Abstract][Full Text] [Related]
12. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
Ibrahim HN; Rosenberg ME; Hostetter TH
Semin Nephrol; 1997 Sep; 17(5):431-40. PubMed ID: 9316211
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II and its receptors in the diabetic kidney.
Burns KD
Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
[TBL] [Abstract][Full Text] [Related]
14. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
Brewster UC; Perazella MA
Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
[TBL] [Abstract][Full Text] [Related]
15. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
Weinberg MS; Weinberg AJ; Zappe DH
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
[No Abstract] [Full Text] [Related]
16. Aldosterone in progressive renal disease.
Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
Semin Nephrol; 2001 Nov; 21(6):573-9. PubMed ID: 11709805
[TBL] [Abstract][Full Text] [Related]
17. New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?
Gromotowicz-Poplawska A; Szoka P; Kolodziejczyk P; Kramkowski K; Wojewodzka-Zelezniakowicz M; Chabielska E
Exp Biol Med (Maywood); 2016 Nov; 241(17):1888-1899. PubMed ID: 27439538
[TBL] [Abstract][Full Text] [Related]
18. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors.
Zhuo J; Moeller I; Jenkins T; Chai SY; Allen AM; Ohishi M; Mendelsohn FA
J Hypertens; 1998 Dec; 16(12 Pt 2):2027-37. PubMed ID: 9886893
[TBL] [Abstract][Full Text] [Related]
19. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
